Tainá Larissa Lubschinski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tainá Larissa Lubschinski has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Monguilhott Dalmarco
Department of Clinical Analysis, Center of Health Sciences, Federal University of Santa Catarina (UFSC), Campus Universitario‑Trindade, Florianopolis, Brazil
5 shared publications - Marcus Mandolesi Sa
Department of Chemistry, Federal University of Santa Catarina, Campus Universitario‑Trindade, Florianopolis, Brazil
3 shared publications - Eduarda Talita Bramorski Mohr
Laboratório Bridge, Brasil; Universidade Federal de Santa Catarina (UFSC), Brasil
2 shared publications - Eduarda Talita Bramorski Mohr
Department of Clinical Analysis, Center of Health Sciences, Federal University of Santa Catarina (UFSC), Campus Universitario‑Trindade, Florianopolis, Brazil
2 shared publications - Flora Aparecida Milton
Laboratory of Molecular Pharmacology, School of Health Sciences, University of Brasília (UnB), Brasília, Brazil
2 shared publications - José Roberto Santin
Postgraduate Program in Pharmaceutical Sciences, Universidade Do Vale Do Itajaí (UNIVALI), Itajaí, Brazil
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (11) , 7321-7322
Correction: The anti‑inflammatory activity of 2‑iminothiazolidines: the role of PPAR-γ and M2 macrophage subpopulations
- 12 October 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (11) , 7321-7322
Open AccessCorrection: The anti‑inflammatory activity of 2‑iminothiazolidines: the role of PPAR-γ and M2 macrophage subpopulations
- Open Access
- 22 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (6) , 3817-3833
The anti‑inflammatory activity of 2‑iminothiazolidines: the role of PPARγ and M2 macrophage subpopulations
Thiazolidine derivatives exert anti-inflammatory effects by inhibiting the NF-κB pathway and promoting macrophage polarization toward the anti-inflammatory M2 phenotype, partially through PPARγ activation. Our previous work identified thiazolidine derivative 13 [methyl 2-(benzoylimino)-3-methyl-4-(4-nitrobenzyl)-1,3-thiazolidine-4-carboxylate] as a potent immunomodulator that reduces pro-inflammatory mediators and enhances anti-inflammatory markers. However, its direct interaction with PPARγ remains unclear. This study aims to evaluate whether thiazolidine 13 activates PPARγ and contributes to M2 macrophage polarization using LPS-stimulated RAW 264.7 cells, cell transactivation assay and reporter gene (Hella cells), LPS-stimulated THP-1 cells, and molecular docking analysis. Compound 13 reduced NO₂⁻ production, CD80 expression, and pro-inflammatory cytokines while increasing IL-10, TGF-β, and CD206 in LPS-stimulated RAW 264.7 macrophages. Compound 13 also inhibited NO production in LPS-stimulated THP-1 cells. These effects were only partially reversed by PPARγ antagonists, suggesting additional PPARγ-independent mechanisms, while the induction of CD206 was closely linked to partial PPARγ activation. Docking studies supported this profile, showing that the (S) enantiomer of thiazolidine 13 adopts a binding mode typical of partial PPARγ agonists and exhibits a higher predicted affinity than the (R) enantiomer. Compound 13 acts as a partial PPARγ modulator capable of shifting macrophages from a pro-inflammatory toward an anti-inflammatory phenotype (M2-like). This dual action relies on the inhibition of NF-κB signaling and partial PPARγ activation. The predominance of the M2-like subpopulation, underscores its role in resolving inflammation and promoting tissue repair. Graphical abstract The alternative text for this image may have been generated using AI.
- 22 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (6) , 3817-3833
Open AccessThe anti‑inflammatory activity of 2‑iminothiazolidines: the role of PPARγ and M2 macrophage subpopulations
Thiazolidine derivatives exert anti-inflammatory effects by inhibiting the NF-κB pathway and promoting macrophage polarization toward the anti-inflammatory M2 phenotype, partially through PPARγ activation. Our previous work identified thiazolidine derivative 13 [methyl 2-(benzoylimino)-3-methyl-4-(4-nitrobenzyl)-1,3-thiazolidine-4-carboxylate] as a potent immunomodulator that reduces pro-inflammatory mediators and enhances anti-inflammatory markers. However, its direct interaction with PPARγ remains unclear. This study aims to evaluate whether thiazolidine 13 activates PPARγ and contributes to M2 macrophage polarization using LPS-stimulated RAW 264.7 cells, cell transactivation assay and reporter gene (Hella cells), LPS-stimulated THP-1 cells, and molecular docking analysis. Compound 13 reduced NO₂⁻ production, CD80 expression, and pro-inflammatory cytokines while increasing IL-10, TGF-β, and CD206 in LPS-stimulated RAW 264.7 macrophages. Compound 13 also inhibited NO production in LPS-stimulated THP-1 cells. These effects were only partially reversed by PPARγ antagonists, suggesting additional PPARγ-independent mechanisms, while the induction of CD206 was closely linked to partial PPARγ activation. Docking studies supported this profile, showing that the (S) enantiomer of thiazolidine 13 adopts a binding mode typical of partial PPARγ agonists and exhibits a higher predicted affinity than the (R) enantiomer. Compound 13 acts as a partial PPARγ modulator capable of shifting macrophages from a pro-inflammatory toward an anti-inflammatory phenotype (M2-like). This dual action relies on the inhibition of NF-κB signaling and partial PPARγ activation. The predominance of the M2-like subpopulation, underscores its role in resolving inflammation and promoting tissue repair. Graphical abstract The alternative text for this image may have been generated using AI.
- 21 August 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 39 (10) , 2895-2911
Thiazolidines derivatives and their anti-inflammatory activity in LPS-induced RAW 264.7 macrophages: a systematic review and meta-analysis
Thiazolidine scaffolds have been investigated for decades, due to their wide range of biological activity. In this way, the main objective of this systematic review was to elucidate the anti-inflammatory activity of thiazolidine derivatives against nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. From 9718 identified registers, 13 articles were included, where 11 studies evaluated thiazolidinediones. The summary of relevance demonstrated that seven studies (53.8%) were relevant without restrictions, and 6 (46.2%) were relevant with restrictions. The certainty in cumulative evidence was considered moderate and the six studies included in the meta-analysis demonstrated the positive activity of thiazolidinediones against NO production when compared to the negative LPS control.
- 21 August 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 39 (10) , 2895-2911
Thiazolidines derivatives and their anti-inflammatory activity in LPS-induced RAW 264.7 macrophages: a systematic review and meta-analysis
Thiazolidine scaffolds have been investigated for decades, due to their wide range of biological activity. In this way, the main objective of this systematic review was to elucidate the anti-inflammatory activity of thiazolidine derivatives against nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. From 9718 identified registers, 13 articles were included, where 11 studies evaluated thiazolidinediones. The summary of relevance demonstrated that seven studies (53.8%) were relevant without restrictions, and 6 (46.2%) were relevant with restrictions. The certainty in cumulative evidence was considered moderate and the six studies included in the meta-analysis demonstrated the positive activity of thiazolidinediones against NO production when compared to the negative LPS control.
- 6 June 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (5) , 1185-1190
Anti-inflammatory and Antioxidant Activity of Eugenial D from Eugenia astringens
- 6 June 2024
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (5) , 1185-1190
Anti-inflammatory and Antioxidant Activity of Eugenial D from Eugenia astringens
- Open Access
- 17 February 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024, 1-12
Interference in Macrophage Balance (M1/M2): The Mechanism of Action Responsible for the Anti-Inflammatory Effect of a Fluorophenyl-Substituted Imidazole
Traditionally, the treatment of inflammatory conditions has focused on the inhibition of inflammatory mediator production; however, many conditions are refractory to this classical approach. Recently, an alternative has been presented by researchers to solve this problem: The immunomodulation of cells closely related to inflammation. Hence, macrophages, a critical key in both innate and acquired immunity, have been presented as an alternative target for the development of new medicines. In this work, we tested the fluorophenyl-imidazole for its anti-inflammatory activity and possible immunomodulatory effect on RAW 264.7 macrophages. We also evaluated the anti-inflammatory effect of the compound, and the macrophage repolarization to M2 was confirmed by the ability of the compound to reduce the M1 markers TNF-α, IL-6, MCP-1, IL-12p70, IFN-γ, and TLR4, the high levels of p65 phosphorylated, iNOS and COX-2 mRNA expression, and the fact that the compound was not able to induce the production of M1 markers when used in macrophages without lipopolysaccharide (LPS) stimulation. Moreover, fluorophenyl-imidazole had the ability to increase the M2 markers IL-4, IL-13, CD206, apoptosis and phagocytosis levels, arginase-1, and FIZZ-1 mRNA expression before LPS stimulation. Similarly, it was also able to induce the production of these same M2 markers in macrophages without being induced with LPS. These results reinforce the affirmation that the fluorophenyl-imidazole has an important anti-inflammatory effect and demonstrates that this effect is due to immunomodulatory activity, having the ability to trigger a repolarization of macrophages from M1 to M2a. These facts suggest that this molecule could be used as an alternative scaffold for the development of a new medicine to treat inflammatory conditions, where the anti-inflammatory and proregenerative properties of M2a macrophages are desired.
- 17 February 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024, 1-12
Open AccessInterference in Macrophage Balance (M1/M2): The Mechanism of Action Responsible for the Anti-Inflammatory Effect of a Fluorophenyl-Substituted Imidazole
Traditionally, the treatment of inflammatory conditions has focused on the inhibition of inflammatory mediator production; however, many conditions are refractory to this classical approach. Recently, an alternative has been presented by researchers to solve this problem: The immunomodulation of cells closely related to inflammation. Hence, macrophages, a critical key in both innate and acquired immunity, have been presented as an alternative target for the development of new medicines. In this work, we tested the fluorophenyl-imidazole for its anti-inflammatory activity and possible immunomodulatory effect on RAW 264.7 macrophages. We also evaluated the anti-inflammatory effect of the compound, and the macrophage repolarization to M2 was confirmed by the ability of the compound to reduce the M1 markers TNF-α, IL-6, MCP-1, IL-12p70, IFN-γ, and TLR4, the high levels of p65 phosphorylated, iNOS and COX-2 mRNA expression, and the fact that the compound was not able to induce the production of M1 markers when used in macrophages without lipopolysaccharide (LPS) stimulation. Moreover, fluorophenyl-imidazole had the ability to increase the M2 markers IL-4, IL-13, CD206, apoptosis and phagocytosis levels, arginase-1, and FIZZ-1 mRNA expression before LPS stimulation. Similarly, it was also able to induce the production of these same M2 markers in macrophages without being induced with LPS. These results reinforce the affirmation that the fluorophenyl-imidazole has an important anti-inflammatory effect and demonstrates that this effect is due to immunomodulatory activity, having the ability to trigger a repolarization of macrophages from M1 to M2a. These facts suggest that this molecule could be used as an alternative scaffold for the development of a new medicine to treat inflammatory conditions, where the anti-inflammatory and proregenerative properties of M2a macrophages are desired.